了解和治疗肌缩侧面硬化症 (ALS) 的进展:全面审查
Deepal Gupta1, Sunita Vagha2, Hitaansh Dhingra1
1Medicine, Jawaharlal Nehru Medical College, Datta Meghe Institute of Higher Education and Research, Wardha, IND.
Cureus
|December 13, 2023
概括
肌缩侧面硬化症 (ALS) 的管理仍然具有挑战性. 实验性药物,基因改造和辅助疗法的最新进展为阻止疾病进展和改善患者生活质量提供了新的希望.
科学领域:
- 神经科学是一个神经科学.
- 神经学 神经学
- 遗传学 是一个遗传学.
背景情况:
- 肌缩侧面硬化症 (ALS) 是一种致命的神经退行性疾病,影响中枢神经系统 (CNS).
- 目前对ALS的诊断和预后方法是不理想的.
- 早期干预对于改善患者的生存和治疗结果至关重要.
研究的目的:
- 提供对ALS新兴治疗策略的全面概述.
- 为了突出最近在药物,基因改造和支持性护理方面的进展.
主要方法:
- 关于创新的ALS治疗方法的最新科学文献的审查.
- 综述实验性药物,基因改造技术和症状疗法.
- 对专注于改善ALS患者生活质量的研究进行分析.
主要成果:
- 两种药物,利卢和埃达拉,在预期寿命方面提供了微小的增加.
- 许多先进的实验药物正在开发中.
- 基因改造和症状/康复疗法在阻止疾病进展和提高生活质量方面表现有前途.
结论:
- 尽管目前治疗疗效有限,但最近的治疗创新为ALS患者提供了重大希望.
- 对新药和新疗法的持续研究对于对抗ALS至关重要.
- 结合创新的治疗方法和支持性护理的多方面的方法是改善ALS患者治疗结果的关键.
相关概念视频
Parkinson's Disease: Overview
556
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
556
Alzheimer's Disease: Overview
492
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
492
Alzheimer's Disease: Treatment
195
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
195
Myasthenia Gravis: Overview and Treatment
1.5K
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
1.5K
Parkinson's Disease: Treatment
274
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
274
Lysosomal Hydrolases
3.8K
Lysosomes are the site for the degradation of macromolecules and biological polymers released during membrane trafficking events such as secretory, endocytic, autophagic, and phagocytic pathways. The membrane-enclosed area of the lysosome, called the lumen, contains hydrolytic enzymes active in an acidic environment. These acid hydrolases are functional at a pH between 4.5 and 5 and are involved in cellular processes such as cell signaling, energy metabolism, restoration of the plasma membrane,...
3.8K


